Medical Experts Rename Polycystic Ovarian Syndrome to Address Broader Health Impacts
Polycystic ovarian syndrome (PCOS), a condition affecting approximately 170 million people globally, has been renamed to polyendocrine metabolic ovarian syndrome (PMOS). This change, announced in a paper published in the Lancet, aims to better reflect the condition's extensive effects on various bodily systems, including metabolic, endocrine, cardiovascular, reproductive, and dermatological systems, as well as mental health. Dr. Melanie Cree, a pediatric endocrinologist at the University of Colorado Anschutz, emphasized that the renaming is not merely a semantic change but a recognition of the full spectrum of patient experiences. Historically, PCOS was viewed primarily as a gynecological issue, often leading to misdiagnosis and stigma. The new name seeks to improve diagnosis, treatment, and research by acknowledging the condition's complexity. 
